Melanoma Therapeutics Market Analysis By Therapy, By Drugs (Opdivo, Yervoy, Mekinist+Tafinlar, Keytruda, Cotellic, Zelboraf, Imlygic, Generics), And Segment Forecasts, 2014 - 2025
The global melanoma therapeutics market is expected to reach USD 12.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing incidence of chronic diseases such as melanoma, skin cancer, and skin allergies is an important driver of the market.
According to CDC, over 71,943 people were affected by melanoma in 2013. The American Cancer Society estimates that this number will go up to 87,100 in 2017, thus highlighting the need for melanoma drugs over the forecast period.
Increasing number of FDA approvals and introduction of novel therapeutics with enhanced efficacy are also anticipated to present growth opportunities. Within a period of 6 years, i.e., from 2011 to 2016, around eight biologics have been approved for the treatment of this disease, which include Opdivo, Yervoy, Cotellic, Zelboraf, Keytruda, Mekinist, Tafinlar, and Imlygic.
Companies are undertaking various R&D activities to find new indications for existing products and development of innovative molecules. For instance, in September 2014, the U.S. FDA approved patented drug Keytruda (Merck & Co., Inc.) to treat metastatic melanoma, thereby extending the therapeutic application of its product. This drug was initially approved for treatment of non-small cell lung cancer.
Furthermore, many pharmaceutical companies in the U.S., Europe, and Asia Pacific are focusing on development of new biologics. For instance, in March 2017, Daiichi Sankyo Company, Limited announced a collaborative drug discovery project—Take a New challenge for Drug discovery (TaNeDS)—to facilitate new drug development through collaborations. Moreover, it entered into a strategic research collaboration with AgonOX, Inc. to develop new immunotherapy drugs for the immuno-oncology segment. Approval of novel products over the forecast period is anticipated to boost market growth.
Further Key Findings From the Study Suggest:
According to CDC, over 71,943 people were affected by melanoma in 2013. The American Cancer Society estimates that this number will go up to 87,100 in 2017, thus highlighting the need for melanoma drugs over the forecast period.
Increasing number of FDA approvals and introduction of novel therapeutics with enhanced efficacy are also anticipated to present growth opportunities. Within a period of 6 years, i.e., from 2011 to 2016, around eight biologics have been approved for the treatment of this disease, which include Opdivo, Yervoy, Cotellic, Zelboraf, Keytruda, Mekinist, Tafinlar, and Imlygic.
Companies are undertaking various R&D activities to find new indications for existing products and development of innovative molecules. For instance, in September 2014, the U.S. FDA approved patented drug Keytruda (Merck & Co., Inc.) to treat metastatic melanoma, thereby extending the therapeutic application of its product. This drug was initially approved for treatment of non-small cell lung cancer.
Furthermore, many pharmaceutical companies in the U.S., Europe, and Asia Pacific are focusing on development of new biologics. For instance, in March 2017, Daiichi Sankyo Company, Limited announced a collaborative drug discovery project—Take a New challenge for Drug discovery (TaNeDS)—to facilitate new drug development through collaborations. Moreover, it entered into a strategic research collaboration with AgonOX, Inc. to develop new immunotherapy drugs for the immuno-oncology segment. Approval of novel products over the forecast period is anticipated to boost market growth.
Further Key Findings From the Study Suggest:
- Targeted therapy segment is expected to show lucrative growth owing to benefits such as low adverse effects and higher efficiency
- Branded drugs held a dominant share of the industry because of patent exclusivity
- Biologics, such as Opdivo and Cotellic, are expected to exhibit lucrative growth over the forecast period owing to increase adoption and advantages such improved therapeutic effects
- The patent for Yervoy will expire in 2022 in the U.S. and in 2020 in Europe. This is expected to provide growth opportunities for new market entrants
- Asia Pacific is expected to exhibit lucrative CAGR over the forecast period
- Key market players are increasing R&D efforts for discovery and development of novel drugs for the treatment of melanoma
CHAPTER 1 RESEARCH METHODOLOGY
1.1 Country-wise Market: Base Estimates
1.1.1 Global market: CAGR calculation
1.1.2 Region-based segment share calculation
1.2 Research Scope & Assumptions
1.3 List of Data Sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 MELANOMA THERAPEUTICS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increasing incidence of skin-related disorders such as skin cancer and skin allergies
3.2.2 Increasing initiatives from public and private organizations
3.2.3 Presence of strong emerging pipeline
3.3 Market Restraint Analysis
3.3.1 High cost associated with various therapies
3.4 Penetration & Growth Prospect Mapping
3.5 Melanoma Therapeutics - SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
3.6 Market Analysis - Porter’s
CHAPTER 4 MELANOMA THERAPEUTICS MARKET: THERAPY ESTIMATES & TREND ANALYSIS
4.1 Melanoma Therapeutics Market: Therapy Movement Analysis
4.2 Chemotherapy
4.2.1 Chemotherapy market, 2014 - 2025 (USD Million)
4.3 Immunotherapy
4.3.1 Immunotherapy market, 2014 - 2025 (USD Million)
4.4 Targeted Therapy
4.4.1 Targeted therapy market, 2014 - 2025 (USD Million)
4.5 Radiation Therapy
4.5.1 Radiation therapy market, 2014 - 2025 (USD Million)
CHAPTER 5 MELANOMA THERAPEUTICS MARKET: DRUG ESTIMATES & TREND ANALYSIS
5.1 Melanoma Therapeutics Market: Drug Movement Analysis
5.2 Branded Drugs
5.2.1 Branded drugs market, 2014 - 2025 (USD Million)
5.2.2 Opdivo
5.2.5.1 Opdivo market, 2014 - 2025 (USD Million)
5.2.3 Yervoy
5.2.5.1 Yervoy market, 2014 - 2025 (USD Million)
5.2.4 Mekinist+Tafinlar
5.2.5.1 Mekinist+Tafinlar market, 2014 - 2025 (USD Million)
5.2.5 Keytruda
5.2.5.1 Keytruda market, 2014 - 2025 (USD Million)
5.2.6 Cotellic
5.2.5.1 Cotellic market, 2014 - 2025 (USD Million)
5.2.7 Zelboraf
5.2.5.1 Zelboraf market, 2014 - 2025 (USD Million)
5.2.8 Imlygic
5.2.5.1 Imlygic market, 2014 - 2025 (USD Million)
5.3 Generic Drugs
5.3.1 Generic drugs market, 2014 - 2025 (USD Million)
CHAPTER 6 MELANOMA THERAPEUTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY THERAPY, AND DRUG
6.1 Melanoma Therapeutics Market Share by Region, 2016& 2025
6.2 North America
6.2.1 North America melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.2.2 North America melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.2.3 North America melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.2.4 U.S.
6.2.4.1 U.S. melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.2.4.2 U.S. melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.2.5 Canada
6.2.5.1 Canada melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.2.5.2 Canada melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.3.2 Europe melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.3.3 Europe melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.3.4 UK
6.3.4.1 UK melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.3.4.2 UK melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.3.5 Germany
6.3.5.1 Germany melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.3.5.2 Germany melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.4.2 Asia Pacific melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.4.3 Asia Pacific melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.4.4 Japan
6.4.4.1 Japan melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.4.4.2 Japan melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.4.5 China
6.4.5.1 China melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.4.5.2 China melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.4.6 India
6.4.6.1 India melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.4.6.2 India melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.5.2 Latin America melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.5.3 Latin America melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.5.4 Brazil
6.5.4.1 Brazil melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.5.4.2 Brazil melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.5.5 Mexico
6.5.5.1 Mexico melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.5.5.2 Mexico melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.6.2 MEA melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.6.3 MEA melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.6.4 South Africa
6.6.4.1 South Africa melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.6.4.2 South Africa melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Strategy Framework
7.2 Market Participation
7.3 Company Profiles
7.3.1 AstraZeneca
7.3.1.1 Company overview
7.3.1.2 Financial performance
7.3.1.3 Strategic initiatives
7.3.2 Amgen, Inc.
7.3.2.1 Company overview
7.3.2.2 Financial performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic initiatives
7.3.3 F. Hoffman-La Roche Ltd.
7.3.3.1 Company overview
7.3.3.2 Financial performance
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Bristol-Myers Squibb Company
7.3.4.1 Company overview
7.3.4.2 Financial performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.5 Novartis AG
7.3.5.1 Company overview
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.5.4 Strategic initiatives
7.3.6 Merck & Co., Inc.
7.3.6.1 Company overview
7.3.6.2 Financial performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic initiatives
7.3.7 Daiichi Sankyo Company, Limited
7.3.7.1 Company overview
7.3.7.2 Financial performance
7.3.7.3 Strategic initiatives
7.3.8 AB Sciences
7.3.8.1 Company overview
7.3.8.2 Financial performance
7.3.8.3 Strategic initiatives
1.1 Country-wise Market: Base Estimates
1.1.1 Global market: CAGR calculation
1.1.2 Region-based segment share calculation
1.2 Research Scope & Assumptions
1.3 List of Data Sources
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Snapshot
CHAPTER 3 MELANOMA THERAPEUTICS MARKET VARIABLES, TRENDS & SCOPE
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increasing incidence of skin-related disorders such as skin cancer and skin allergies
3.2.2 Increasing initiatives from public and private organizations
3.2.3 Presence of strong emerging pipeline
3.3 Market Restraint Analysis
3.3.1 High cost associated with various therapies
3.4 Penetration & Growth Prospect Mapping
3.5 Melanoma Therapeutics - SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
3.6 Market Analysis - Porter’s
CHAPTER 4 MELANOMA THERAPEUTICS MARKET: THERAPY ESTIMATES & TREND ANALYSIS
4.1 Melanoma Therapeutics Market: Therapy Movement Analysis
4.2 Chemotherapy
4.2.1 Chemotherapy market, 2014 - 2025 (USD Million)
4.3 Immunotherapy
4.3.1 Immunotherapy market, 2014 - 2025 (USD Million)
4.4 Targeted Therapy
4.4.1 Targeted therapy market, 2014 - 2025 (USD Million)
4.5 Radiation Therapy
4.5.1 Radiation therapy market, 2014 - 2025 (USD Million)
CHAPTER 5 MELANOMA THERAPEUTICS MARKET: DRUG ESTIMATES & TREND ANALYSIS
5.1 Melanoma Therapeutics Market: Drug Movement Analysis
5.2 Branded Drugs
5.2.1 Branded drugs market, 2014 - 2025 (USD Million)
5.2.2 Opdivo
5.2.5.1 Opdivo market, 2014 - 2025 (USD Million)
5.2.3 Yervoy
5.2.5.1 Yervoy market, 2014 - 2025 (USD Million)
5.2.4 Mekinist+Tafinlar
5.2.5.1 Mekinist+Tafinlar market, 2014 - 2025 (USD Million)
5.2.5 Keytruda
5.2.5.1 Keytruda market, 2014 - 2025 (USD Million)
5.2.6 Cotellic
5.2.5.1 Cotellic market, 2014 - 2025 (USD Million)
5.2.7 Zelboraf
5.2.5.1 Zelboraf market, 2014 - 2025 (USD Million)
5.2.8 Imlygic
5.2.5.1 Imlygic market, 2014 - 2025 (USD Million)
5.3 Generic Drugs
5.3.1 Generic drugs market, 2014 - 2025 (USD Million)
CHAPTER 6 MELANOMA THERAPEUTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS, BY THERAPY, AND DRUG
6.1 Melanoma Therapeutics Market Share by Region, 2016& 2025
6.2 North America
6.2.1 North America melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.2.2 North America melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.2.3 North America melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.2.4 U.S.
6.2.4.1 U.S. melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.2.4.2 U.S. melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.2.5 Canada
6.2.5.1 Canada melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.2.5.2 Canada melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.3.2 Europe melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.3.3 Europe melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.3.4 UK
6.3.4.1 UK melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.3.4.2 UK melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.3.5 Germany
6.3.5.1 Germany melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.3.5.2 Germany melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.4.2 Asia Pacific melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.4.3 Asia Pacific melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.4.4 Japan
6.4.4.1 Japan melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.4.4.2 Japan melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.4.5 China
6.4.5.1 China melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.4.5.2 China melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.4.6 India
6.4.6.1 India melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.4.6.2 India melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.5.2 Latin America melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.5.3 Latin America melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.5.4 Brazil
6.5.4.1 Brazil melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.5.4.2 Brazil melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.5.5 Mexico
6.5.5.1 Mexico melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.5.5.2 Mexico melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA melanoma therapeutics market, by country, 2014 - 2025 (USD Million)
6.6.2 MEA melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.6.3 MEA melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
6.6.4 South Africa
6.6.4.1 South Africa melanoma therapeutics market, by therapy, 2014 - 2025 (USD Million)
6.6.4.2 South Africa melanoma therapeutics market, by drugs, 2014 - 2025 (USD Million)
CHAPTER 7 COMPETITIVE LANDSCAPE
7.1 Strategy Framework
7.2 Market Participation
7.3 Company Profiles
7.3.1 AstraZeneca
7.3.1.1 Company overview
7.3.1.2 Financial performance
7.3.1.3 Strategic initiatives
7.3.2 Amgen, Inc.
7.3.2.1 Company overview
7.3.2.2 Financial performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic initiatives
7.3.3 F. Hoffman-La Roche Ltd.
7.3.3.1 Company overview
7.3.3.2 Financial performance
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Bristol-Myers Squibb Company
7.3.4.1 Company overview
7.3.4.2 Financial performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.5 Novartis AG
7.3.5.1 Company overview
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.5.4 Strategic initiatives
7.3.6 Merck & Co., Inc.
7.3.6.1 Company overview
7.3.6.2 Financial performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic initiatives
7.3.7 Daiichi Sankyo Company, Limited
7.3.7.1 Company overview
7.3.7.2 Financial performance
7.3.7.3 Strategic initiatives
7.3.8 AB Sciences
7.3.8.1 Company overview
7.3.8.2 Financial performance
7.3.8.3 Strategic initiatives
LIST OF TABLES
TABLE 1 Country share estimation
TABLE 2 North America melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 3 North America melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 4 U.S. melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 5 U.S. melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 6 Canada melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 7 Canada melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 8 Europe melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 9 Europe melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 10 UK melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 11 UK melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 12 Germany melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 13 Germany melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 14 Asia Pacific melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 15 Asia Pacific melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 16 Japan melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 17 Japan melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 18 China melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 19 China melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 20 India melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 21 India melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 22 Latin America melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 23 Latin America melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 24 Brazil melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 25 Brazil melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 26 Mexico melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 27 Mexico melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 28 MEA melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 29 MEA melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 30 South Africa melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 31 South Africa melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 1 Country share estimation
TABLE 2 North America melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 3 North America melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 4 U.S. melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 5 U.S. melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 6 Canada melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 7 Canada melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 8 Europe melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 9 Europe melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 10 UK melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 11 UK melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 12 Germany melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 13 Germany melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 14 Asia Pacific melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 15 Asia Pacific melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 16 Japan melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 17 Japan melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 18 China melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 19 China melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 20 India melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 21 India melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 22 Latin America melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 23 Latin America melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 24 Brazil melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 25 Brazil melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 26 Mexico melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 27 Mexico melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 28 MEA melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 29 MEA melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
TABLE 30 South Africa melanoma therapeutics market, by therapy, 2014 - 2025 (USD million)
TABLE 31 South Africa melanoma therapeutics market, by dugs, 2014 - 2025 (USD million)
LIST OF FIGURES
FIG. 1 Market summary
FIG. 2 Market trends &outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Melanoma therapeutics market therapy outlook: key takeaways
FIG. 10 Melanoma therapeutics market: Therapy movement analysis
FIG. 11 Chemotherapy market, 2014 - 2025 (USD Million)
FIG. 12 Immunotherapy market, 2014 - 2025 (USD Million)
FIG. 13 Targeted therapy market, 2014 - 2025 (USD Million)
FIG. 14 Radiation therapy market, 2014 - 2025 (USD Million)
FIG. 15 Melanoma therapeutics market drug outlook: key takeaways
FIG. 16 Melanoma therapeutics market: Drug movement analysis
FIG. 17 Branded drugs market, 2014 - 2025 (USD Million)
FIG. 18 Opdivo market, 2014 - 2025 (USD Million)
FIG. 19 Yervoy market, 2014 - 2025 (USD Million)
FIG. 20 Mekinist+Tafinlar market, 2014 - 2025 (USD Million)
FIG. 21 Keytruda market, 2014 - 2025 (USD Million)
FIG. 22 Cotellic market, 2014 - 2025 (USD Million)
FIG. 23 Zelboraf market, 2014 - 2025 (USD Million)
FIG. 24 Imlygic market, 2014 - 2025 (USD Million)
FIG. 25 Generic drugs market, 2014 - 2025 (USD Million)
FIG. 26 Regional market place: Key takeaways
FIG. 27 Regional outlook, 2016 & 2025
FIG. 28 North America melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 29 U.S. melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 30 Canada melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 31 Europe melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 32 UK melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 33 Germany melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 34 Asia Pacific melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 35 Japan melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 36 China melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 37 India melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 38 Latin America melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 39 Brazil melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 40 Mexico melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 41 MEA melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 42 South Africa melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 43 Strategy framework
FIG. 44 Participant categorization
FIG. 1 Market summary
FIG. 2 Market trends &outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restraint relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Melanoma therapeutics market therapy outlook: key takeaways
FIG. 10 Melanoma therapeutics market: Therapy movement analysis
FIG. 11 Chemotherapy market, 2014 - 2025 (USD Million)
FIG. 12 Immunotherapy market, 2014 - 2025 (USD Million)
FIG. 13 Targeted therapy market, 2014 - 2025 (USD Million)
FIG. 14 Radiation therapy market, 2014 - 2025 (USD Million)
FIG. 15 Melanoma therapeutics market drug outlook: key takeaways
FIG. 16 Melanoma therapeutics market: Drug movement analysis
FIG. 17 Branded drugs market, 2014 - 2025 (USD Million)
FIG. 18 Opdivo market, 2014 - 2025 (USD Million)
FIG. 19 Yervoy market, 2014 - 2025 (USD Million)
FIG. 20 Mekinist+Tafinlar market, 2014 - 2025 (USD Million)
FIG. 21 Keytruda market, 2014 - 2025 (USD Million)
FIG. 22 Cotellic market, 2014 - 2025 (USD Million)
FIG. 23 Zelboraf market, 2014 - 2025 (USD Million)
FIG. 24 Imlygic market, 2014 - 2025 (USD Million)
FIG. 25 Generic drugs market, 2014 - 2025 (USD Million)
FIG. 26 Regional market place: Key takeaways
FIG. 27 Regional outlook, 2016 & 2025
FIG. 28 North America melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 29 U.S. melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 30 Canada melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 31 Europe melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 32 UK melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 33 Germany melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 34 Asia Pacific melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 35 Japan melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 36 China melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 37 India melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 38 Latin America melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 39 Brazil melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 40 Mexico melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 41 MEA melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 42 South Africa melanoma therapeutics market, 2014 - 2025 (USD Million)
FIG. 43 Strategy framework
FIG. 44 Participant categorization
